Back to Search
DAVID HICKLIN, DMD
DMD
General Practice Dentistry
NPI: 1740312982Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
4261(SC)
Research & Publications (20)
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
PMID 19252838·Methods Mol Biol·2009
7-preclinical
Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse.
PMID 19406950·Endocrinology·2009
7-preclinical
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
PMID 19528458·Anticancer Res·2009
7-preclinical
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
PMID 19082474·Int J Oncol·2009
7-preclinical
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
PMID 18927275·Clin Cancer Res·2008
6-review
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
PMID 18337601·N Engl J Med·2008
8-other
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling.
PMID 18199827·Blood·2008
7-preclinical
Effect of molecular therapeutics on liver regeneration in a murine model.
PMID 18398149·J Clin Oncol·2008
7-preclinical
Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.
PMID 17950526·Cancer Lett·2007
8-other
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.
PMID 17606729·Clin Cancer Res·2007
7-preclinical
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
PMID 17190647·Immunol Invest·2007
6-review
Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy.
PMID 17875787·Clin Cancer Res·2007
6-review
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers.
PMID 17913857·Mol Cancer Ther·2007
7-preclinical
Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
PMID 17699866·Clin Cancer Res·2007
7-preclinical
Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
PMID 18094427·Clin Cancer Res·2007
7-preclinical
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
PMID 17440065·Cancer Res·2007
7-preclinical
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
PMID 17332300·Clin Cancer Res·2007
7-preclinical
Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies.
PMID 17467156·Ultrasound Med Biol·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10 RICHLAND MEDICAL PARK DR STE A
COLUMBIA, SC 29203 - Phone
- (803) 434-6565
Quick Facts
- NPI
- 1740312982
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile